HC Wainwright Issues Positive Outlook for AGIO Earnings

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Agios from ($1.66) to ($1.58) and retains a Buy rating with a $50 price target.
• Agios recently reported ($1.69) EPS, beating consensus of ($1.81), and revenue of $20.75 million versus $13.30 million expected, a 137.7% year‑over‑year increase.
• Analyst sentiment is mixed—six Buys, four Holds and one Sell—yielding an average rating of Hold and an average target price of $41.56, while the stock trades near $28 with a 52‑week range of $22.24–$46.00.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued on Wednesday, April 29th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn ($1.58) per share for the quarter, up from their prior forecast of ($1.66). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.30) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals' Q3 2026 earnings at ($1.55) EPS, Q4 2026 earnings at ($1.52) EPS, FY2026 earnings at ($6.34) EPS, FY2027 earnings at ($5.68) EPS, FY2028 earnings at ($4.81) EPS, FY2029 earnings at ($2.77) EPS and FY2030 earnings at $2.57 EPS.

A number of other analysts have also recently weighed in on the company. Bank of America lowered their price target on Agios Pharmaceuticals from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Tuesday, April 21st. Truist Financial decreased their target price on Agios Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday. JPMorgan Chase & Co. increased their target price on Agios Pharmaceuticals from $31.00 to $36.00 and gave the stock a "neutral" rating in a report on Monday, April 6th. Wall Street Zen upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, March 22nd. Finally, Citigroup increased their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $41.56.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $28.16 on Monday. The business's fifty day moving average price is $29.87 and its two-hundred day moving average price is $30.90. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -3.88 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts' consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million for the quarter, compared to analysts' expectations of $13.30 million. Agios Pharmaceuticals's revenue for the quarter was up 137.7% compared to the same quarter last year.

Insider Activity at Agios Pharmaceuticals

In related news, insider Krishnan Viswanadhan sold 2,959 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the transaction, the insider owned 5,141 shares in the company, valued at $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James William Burns sold 3,280 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,848.80. Following the completion of the sale, the insider owned 49,306 shares of the company's stock, valued at approximately $1,711,411.26. The trade was a 6.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 15,582 shares of company stock valued at $520,405. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently modified their holdings of AGIO. Creative Planning raised its stake in shares of Agios Pharmaceuticals by 2.2% during the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company's stock worth $527,000 after buying an additional 280 shares during the last quarter. Assetmark Inc. boosted its stake in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 362 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company's stock worth $4,393,000 after acquiring an additional 512 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 588 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Agios Pharmaceuticals by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company's stock valued at $796,000 after acquiring an additional 662 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.